Comparison Workspace
Program Compare
Compare up to 6 HearScape records side by side across ownership, modality, stage, evidence, populations, trials, source support, and review notes.
1 Selected Records
URL-shareable comparison set.
| Field | AK-OTOF by Eli Lilly and Akouos Eli Lilly and Company |
|---|---|
| Organization | Company: Eli Lilly and Company |
| Program Type | Therapeutic |
| Modality | Gene Therapy |
| Stage / Status | Phase 2 / Active |
| Review Status | checked · trial |
| Confidence | 95% |
| Target / Gene | OTOF |
| Route / Mode | Intracochlear injection |
| Indications | Hearing Loss; Sensorineural Hearing Loss; Genetic Hearing Loss; OTOF-Related Hearing Loss; Auditory Neuropathy |
| Population Tags | pediatric; adult; congenital; genetic; otof-dfnb9; pre-lingual; bilateral; profound |
| Geography | United States |
| Trials | |
| Source Support | 3 structured sources · 3 URL-backed · clinicaltrials, company |
| Last Reviewed | 2026-05-31 |
| Data Checks | No data flags |
| Mechanism | AAV-mediated OTOF gene replacement is delivered to the cochlea to restore otoferlin function in genetic hearing loss. |
| Notes | Lead Akouos program acquired by Lilly in 2022; Lilly publicly classified OTOF gene therapy as Phase 2 in later annual reports while the ongoing named study remains AK-OTOF-101. |